Birgit Korioth-Schmitz
Overview
Explore the profile of Birgit Korioth-Schmitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Santra S, Sun Y, Korioth-Schmitz B, Fitzgerald J, Charbonneau C, Santos G, et al.
Vaccine
. 2009 Aug;
27(42):5837-45.
PMID: 19660588
Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both...
12.
Cayabyab M, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A, et al.
J Virol
. 2009 Mar;
83(11):5505-13.
PMID: 19297477
While mycobacteria have been proposed as vaccine vectors because of their persistence and safety, little has been done systematically to optimize their immunogenicity in nonhuman primates. We successfully generated recombinant...
13.
Stevceva L, Yoon V, Carville A, Pacheco B, Santosuosso M, Korioth-Schmitz B, et al.
J Immunol
. 2008 Oct;
181(8):5510-21.
PMID: 18832708
Gp120 is a critical component of the envelope of HIV-1. Its role in viral entry is well described. In view of its position on the viral envelope, gp120 is a...
14.
Zahn R, Rett M, Korioth-Schmitz B, Sun Y, Buzby A, Goldstein S, et al.
J Virol
. 2008 Oct;
82(23):11577-88.
PMID: 18829748
African green monkeys (AGM) do not develop overt signs of disease following simian immunodeficiency virus (SIV) infection. While it is still unknown how natural hosts like AGM can cope with...
15.
Letvin N, Rao S, Dang V, Buzby A, Korioth-Schmitz B, Dombagoda D, et al.
J Virol
. 2007 Aug;
81(22):12368-74.
PMID: 17686853
Defining the immune correlates of the protection against human immunodeficiency virus type 1 (HIV-1) acquisition in individuals who are exposed to HIV-1 but do not become infected may provide important...
16.
McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro M, Hensley S, Lin S, et al.
J Virol
. 2007 Apr;
81(12):6594-604.
PMID: 17428852
In this study we compared a prime-boost regimen with two serologically distinct replication-defective adenovirus (Ad) vectors derived from chimpanzee serotypes C68 and C1 expressing Gag, Pol, gp140, and Nef of...
17.
Demberg T, Florese R, Heath M, Larsen K, Kalisz I, Kalyanaraman V, et al.
J Virol
. 2007 Jan;
81(7):3414-27.
PMID: 17229693
We previously demonstrated that replication-competent adenovirus (Ad)-simian immunodeficiency virus (SIV) recombinant prime/protein boost regimens elicit potent immunogenicity and strong, durable protection of rhesus macaques against SIV(mac251). Additionally, native Tat vaccines...
18.
Barouch D, Yang Z, Kong W, Korioth-Schmitz B, Sumida S, Truitt D, et al.
J Virol
. 2005 Jul;
79(14):8828-34.
PMID: 15994776
Plasmid DNA vaccines elicit potent and protective immune responses in numerous small-animal models of infectious diseases. However, their immunogenicity in primates appears less potent. Here we investigate a novel approach...
19.
Santra S, Barouch D, Korioth-Schmitz B, Lord C, Krivulka G, Yu F, et al.
Proc Natl Acad Sci U S A
. 2004 Jul;
101(30):11088-93.
PMID: 15258286
Although a consensus has emerged that an HIV vaccine should elicit a cytotoxic T lymphocyte (CTL) response, the characteristics of an effective vaccine-induced T lymphocyte response remain unclear. We explored...
20.
Letvin N, Huang Y, Chakrabarti B, Xu L, Seaman M, Beaudry K, et al.
J Virol
. 2004 Jun;
78(14):7490-7.
PMID: 15220422
Because a strategy to elicit broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies has not yet been found, the role of an Env immunogen in HIV-1 vaccine candidates remains...